CD274 and choriocarcinoma: Immune checkpoint inhibitors (ICIs) are promising for the treatment of choriocarcinoma since most choriocarcinoma specimens exhibit diffuse and intense PD-L1 immunoreactivity in syncytiotrophoblasts (3).